ABOUT THIS EPISODE
Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001337. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions https://pubmed.ncbi.nlm.nih.gov/37762027/
Pathological Identification of HER2-Low Breast Cancer: Tips, Tricks, and Troubleshooting for the Optimal Test https://pubmed.ncbi.nlm.nih.gov/37077201/
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://pubmed.ncbi.nlm.nih.gov/32954927/
Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles https://pubmed.ncbi.nlm.nih.gov/38132377/
Subtypes of Breast Cancer https://www.ncbi.nlm.nih.gov/books/NBK583808/
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/
Trastuzumab Deruxtecan in Metastatic Breast Cancer With Variable HER2 Expression: The Phase 2 DAISY Trial https://pubmed.ncbi.nlm.nih.gov/37488289/
Decoding TROP2 in Breast Cancer: Significance, Clinical Implications, and Therapeutic Advancements https://pubmed.ncbi.nlm.nih.gov/37954074/
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) https://clinicaltrials.gov/study/NCT06533826
